Is antigen specificity the key to efficient adoptive T-cell therapy?

Immunotherapy

Volumn 3, Issue 4, 2011, Pages 495-505

  Labarriere, Nathalie ^a   Khammari, Amir ^a,b   Lang, Francois ^a,c   Dreno, Brigitte ^a,b  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

adoptive transfer; antigen; HLA; melanoma; peptide; T cell sorting

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; MELANOMA ANTIGEN;

ADOPTIVE T LYMPHOCYTE TRANSFER; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL EFFECTIVENESS; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 79953832305     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.16     Document Type: Review

References (106)

1. Balch CM, Soong SJ, Gershenwald JE et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19(16), 3622-3634 (2001).
2. + T cell reactivity to a model tumor antigen. J. Immunol. 164(2), 562-565 (2000).
3. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2), 137-148 (2004).
4. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005).
5. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
6. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
7. Marrogi AJ, Munshi A, Merogi AJ et al.: Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. Int. J. Cancer 74(5), 492-501 (1997).
8. Clark WH Jr, Elder DE, Guerry DT et al.: Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893-1904 (1989).
9. Clemente CG, Mihm MC Jr, Bufalino R et al.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7), 1303-1310 (1996).
10. Zippelius A, Batard P, Rubio-Godoy V et al.: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64(8), 2865-2873 (2004).
11. Matzinger P: The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
12. Ochsenbein AF, Sierro S, Odermatt B et al.: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411(6841), 1058-1064 (2001).
13. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2(6), 389-400 (2002).
14. Khammari A, Nguyen JM, Pandolfino MC et al.: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 56(11), 1853-1860 (2007).
15. Vignard V, Lemercier B, Lim A et al.: Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 175(7), 4797-4805 (2005).
16. June CH: Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117(6), 1466-1476 (2007).
17. + melanoma-specific T-cell clones, associated with complete and durable clinical response, and with epitope spreading.
18. Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med. 159(2), 495-507 (1984).
19. Rosenberg SA, Lotze MT, Muul LM et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316(15), 889-897 (1987).
20. Rosenberg SA, Lotze MT, Muul LM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313(23), 1485-1492 (1985).
21. Rosenberg SA, Packard BS, Aebersold PM et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988).
22. Dillman RO, Oldham RK, Barth NM et al.: Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68(1), 1-8 (1991).
23. Goedegebuure PS, Douville LM, Li H et al.: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Clin. Oncol. 13(8), 1939-1949 (1995).
24. Jotereau F, Pandolfino MC, Boudart D et al.: High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J. Immunother. 10(6), 405-411 (1991).
25. Pandolfino MC, Labarriere N, Tessier MH et al.: High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement. Cancer Immunol. Immunother. 50(3), 134-140 (2001).
26. Dreno B, Nguyen JM, Khammari A et al.: Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 51(10), 539-546 (2002).
27. Labarriere N, Pandolfino MC, Gervois N et al.: Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol. Immunother. 51(10), 532-538 (2002).
28. Benlalam H, Vignard V, Khammari A et al.: Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol. Immunother. 56(4), 515-526 (2007).
29. Godet Y, Moreau-Aubry A, Guilloux Y et al.: MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J. Exp. Med. 205(11), 2673-2682 (2008).
30. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002). First report of substantial melanoma regression after the infusion of highly selected, autologous tumor-infiltrating lymphocytes, following lymphodepletion.
31. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
32. Robbins PF, Dudley ME, Wunderlich J et al.: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173(12), 7125-7130 (2004).
33. Zhou J, Shen X, Huang J et al.: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175(10), 7046-7052 (2005).
34. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21(2), 233-240 (2009).
35. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174(5), 2591-2601 (2005).
36. + T cells. J. Exp. Med. 202(7), 907-912 (2005).
37. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
38. Besser MJ, Shapira-Frommer R, Treves AJ et al.: Clinical responses in a Phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16(9), 2646-2655 (2010).
39. + T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 64(5), 1595-1599 (2004).
40. Linard B, Bezieau S, Benlalam H et al.: A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Immunol. 168(9), 4802-4808 (2002).
41. Robbins PF, El-Gamil M, Li YF et al.: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183(3), 1185-1192 (1996).
42. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19(11), 7327-7335 (1999).
43. Fijak M, Meinhardt A: The testis in immune privilege. Immunol. Rev. 213, 66-81 (2006).
44. Fiszer D, Kurpisz M: Major histocompatibility complex expression on human, male germ cells: a review. Am. J. Reprod. Immunol. 40(3), 172-176 (1998).
45. van der Bruggen P, Traversari C, Chomez P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991). Reports the identification of the first melanoma-associated antigen. Determinant study for the development of antigen-specific melanoma immunotherapy.
46. Chomez P, De Backer O, Bertrand M et al.: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61(14), 5544-5551 (2001).
47. Chen YT, Scanlan MJ, Sahin U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94(5), 1914-1918 (1997).
48. Lethe B, Lucas S, Michaux L et al.: LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76(6), 903-908 (1998).
49. Gure AO, Wei IJ, Old LJ, Chen YT: The SSX gene family: characterization of 9 complete genes. Int. J. Cancer 101(5), 448-453 (2002).
50. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P: Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer 77(4), 538-542 (1998).
51. Lonchay C, van der Bruggen P, Connerotte T et al.: Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101(Suppl. 2) 14631-14638 (2004).
52. Coulie PG, Brichard V, Van Pel A et al.: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180(1), 35-42 (1994).
53. Kawakami Y, Eliyahu S, Delgado CH et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91(9), 3515-3519 (1994).
54. Brichard V, Van Pel A, Wolfel T et al.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178(2), 489-495 (1993).
55. Bakker AB, Schreurs MW, de Boer AJ et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179(3), 1005-1009 (1994).
56. Godet Y, Desfrancois J, Vignard V et al.: Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Eur. J. Immunol. 40(6), 1786-1794 (2010).
57. Pittet MJ, Zippelius A, Valmori D et al.: Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 23(7), 325-328 (2002).
58. Zippelius A, Pittet MJ, Batard P et al.: Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195(4), 485-494 (2002).
59. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. 155(9), 4486-4491 (1995).
60. Ikeda H, Lethe B, Lehmann F et al.: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2), 199-208 (1997).
61. + T cells specific for PRAME: a target for T-cell therapy. Clin. Cancer Res. 12(10), 3130-3136 (2006).
62. Quintarelli C, Dotti G, Angelis B: Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112(5), 1876-1885 (2008).
63. + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10), 2245-2255 (2009).
64. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24(31), 5060-5069 (2006).
65. Meidenbauer N, Marienhagen J, Laumer M et al.: Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170(4), 2161-2169 (2003).
66. Dudley ME, Wunderlich J, Nishimura MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24(4), 363-373 (2001).
67. Khammari A, Labarriere N, Vignard V et al.: Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. 129(12), 2835-2842 (2009).
68. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99(25), 16168-16173 (2002).
69. Dudley ME, Wunderlich JR, Yang JC et al.: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25(3), 243-251 (2002).
70. Effros RB, Pawelec G: Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion? Immunol. Today 18(9), 450-454 (1997).
71. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6(5), 383-393 (2006).
72. + T cells for effective immunotherapy. Curr. Opin. Immunol. 18(3), 363-370 (2006).
73. + T lymphocytes overexpressing telomerase. J. Immunol. 177(6), 3657-3668 (2006).
74. Schumacher TN: T-cell-receptor gene therapy. Nat. Rev. Immunol. 2(7), 512-519 (2002).
75. Dembic Z, Haas W, Weiss S et al.: Transfer of specificity by murine α and β T-cell receptor genes. Nature 320(6059), 232-238 (1986).
76. Clay TM, Custer MC, Sachs et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 1163(1), 507-513 (1999).
77. Calogero A, Hospers GA, Kruse KM et al.: Retargeting of a T cell line by anti MAGE-3/HLA-A2 α β TCR gene transfer. Anticancer Res. 20(3A), 1793-1799 (2000).
78. Fujio K, Misaki Y, Setoguchi K et al.: Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the α β TCR complex. J. Immunol. 165(1), 528-532 (2000).
79. Stanislawski T, Voss RH, Lotz C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2(10), 962-970 (2001).
80. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006). First clinical study reporting the adoptive cell transfer of autologous peripheral blood lymphocyte transduced with an allogeneic T-cell receptor gene, in metastatic melanoma patients.
81. Cohen CJ, Li YF, El-Gamil M et al.: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67(8), 3898-3903 (2007).
82. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66(17), 8878-8886 (2006).
83. Kuball J, Dossett ML, Wolfl M et al.: Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109(6), 2331-2338 (2007).
84. Bialer G, Horovitz-Fried M, Ya'acobi et al.: Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 184(11), 6232-6241 (2010).
85. Chinnasamy N, Wargo JA, Yu Z, Rao et al.: A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186(2), 685-696 (2011).
86. Eshhar Z: Tumor-specific T bodies: towards clinical application. Cancer Immunol. Immunother. 45(3-4), 131-136 (1997).
87. Jena B, Dotti G, Cooper LJN: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7), 1035-1044 (2010).
88. Cobbold M, Khan N, Pourgheysari B et al.: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202(3), 379-386 (2005).
89. Bodinier M, Peyrat MA, Tournay C et al.: Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat. Med. 6(6), 707-710 (2000). Describes an efficient method to sort antigen-specific T cells, based on α3-mutated HLA-A2 multimers coated on magnetic beads.
90. Labarriere N, Gervois N, Bonnin A et al.: PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol. Immunother. 57(2), 185-195 (2008).
91. Bouquie R, Bonnin A, Bernardeau K et al.: A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol. Immunother. 58(4), 553-566 (2009).
92. + T cell to a fully functional tumor killer cell. Cancer Res. 62(22), 6438-6441 (2002).
93. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 165(8), 4246-4253 (2000).
94. + T cells in the antitumor immune response. J. Exp. Med. 188(12), 2357-2368 (1998).
95. Keene JA, Forman J: Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155(3), 768-782 (1982).
96. + T cells: when, where, and how. Annu. Rev. Immunol. 24, 519-540 (2006).
97. Toes RE, Ossendorp F, Offringa R, Melief CJ: CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189(5), 753-756 (1999).
98. + T cells during the effector phase. J. Exp. Med. 207(11), 2469-2477 (2010).
99. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207(3), 637-650 (2010).
100. Chambers CA, Kuhns MS, Egen JG, Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
101. Attia P, Phan GQ, Maker AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005).
102. Sanderson K, Scotland R, Lee P et al.: Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23(4), 741-750 (2005).
103. Whiteside TL: Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin. Biol. Ther. 10(7), 1019-1035 (2010).
104. Koike N, Pilon-Thomas S, Mule JJ: Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J. Immunother. 31(4), 402-412 (2008).
105. Zhang B, Bowerman NA, Salama JK et al.: Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204(1), 49-55 (2007).
106. Vo DD, Prins RM, Begley JL et al.: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69(22), 8693-8699 (2009).